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Abstract   
According to 2018 National Survey on Drug Use and Health, 7.1% of pregnant women 
smoked marijuana in the past month in 2017. Although this prevalence is expected to 
increase as a growing number of states and countries are now considering legalization, 
there are scarce data on effects of in utero cannabis exposure. For the monitoring of fetal 
cannabis exposure, two methods are employed; self-report and the analysis of biological 
matrix. Due to inaccuracy of self-report, the analysis of neonatal matrixes such as 
meconium, hair, and urine is perferred. Although umbilical cord is becoming a useful 
objective tool to detect in utero drug exposure due to the disadvantages of established 
biological samples, currently there are scarce data about analytical methods and its utility 
to detect cannabis exposure. The objective of this work was to develop a method for the 
determination of 9-tetrahydrocannabinol (THC), 11-hydroxyTHC (THC-OH), 11-nor-9-
carboxy-THC (THCCOOH), 8--11-dihydroxyTHC (THC-diOH), THC and THCCOOH 
glucuronides, and cannabidiol (CBD) in umbilical cord by liquid chromatography tandem 
mass spectrometry (LC-MSMS) with dual ionization source (DUIS). Umbilical cord 
samples (0.5g) were homogenized in methanol and extracted by solid phase extraction. 
Reversed-phase chromatographic separation was performed in 14 min, and two transitions 
per analyte were monitored in multiple reaction monitoring mode. Method validation 
included linearity (1-10 to 20-200ng/g), imprecision (4.1-23.4%), accuracy (87.5-111.4%), 
matrix effect (-54.8 to -5.8%), extraction efficiency (25-45.6%), limits of detection and 
quantification (1-10ng/g), and endogenous/exogenous interferences (not detected). The 
method was applied to 13 authentic samples from cannabis-exposed newborns, which 






tested positive for THCCOOH-glucuronide (1.6-19.1ng/g). We developed and validated a 
specific and sensitive method for the simultaneous determination of THC, its metabolites, 
including THC and THCCOOH glucuronides, and CBD in umbilical cord samples by LC-
MSMS. The analysis of authentic samples showed the umbilical cord usefulness to detect 
cannabis in utero exposure. 
 






Cannabis is the one of the oldest and most widely used illicit drugs in the world. 
Due to the current increasingly permissive attitudes towards cannabis use and its 
legalization, the prevalence of cannabis has increased in recent years in the USA. 
According to National Survey on Drug Use and Health (NSDUH) (Center for Behavioral 
Health Statistics and Quality, 2018), 15 % of the population aged 12 or older reported past-
year cannabis use in 2017. This prevalence was higher among men (17.8%) than women 
(12.5%), but both genders showed an increase (+5.3% men, +4.8% women) as in 2015 
(Center for Behavioral Health Statistics and Quality, 2016). Focusing on the women group, 
prevalence for pregnant women past-month cannabis users also increased from 3.4 % in 
2015 to 7.1% in 2017 (Center for Behavioral Health Statistics and Quality, 2018) .  
Although the number of pregnant women using cannabis is rising, the adverse 
effects of fetal cannabis exposure are still less studied than the effects due to other illicit 
drugs (Gunn et al., 2016). Fetal cannabis exposure may produce low birth weight, preterm 
labor, and more requirement to place the newborn in the NICU/ICU (Gunn et al., 2016; 
Hayatbakhsh et al., 2012; Merritt, Wilkinson, and Chervenack, 2016; Fergusson, Horwood, 
Northstone, ALSPAC Study Team, 2002). However, there are no studies available that 
rigorously evaluate the impact of cannabis exposure on the developing fetus. The critical 
limitation in prior efforts has been the inaccuracy of exposure assessment. 
To monitor drug exposure during pregnancy, two methods are commonly 
performed: self- report and analysis of biological samples. Although self-report is the most 
economic and common method, maternal interviews may be unreliable due to 





biological samples offer a more objective and reliable approach (Gray and Huestis, 2007; 
Lozano et al., 2007; Concheiro-Guisan and Concheiro, 2014). Meconium, neonatal hair 
and urine have been used to detect in utero drug exposure since they reflect direct fetal 
exposure to drugs (Lozano et al., 2007). Neonatal urine offers a short window of detection, 
a few days, and its collection is difficult (Lozano et al., 2007). Neonatal hair has an 
extended window of detection (3rd trimester) and it is available for 3 to 5 months after birth 
(Lozano et al., 2007). However, sometimes it is not available (Lozano et al., 2007; Gray 
and Huestis, 2007), or its collection is difficult due to the resistance by parents due to 
cosmetic or cultural reasons (Gray and Huestis, 2007; Montgomery et al., 2008). 
Meconium, the first stool of the newborn, is currently considered the gold standard to detect 
fetal drug exposure during the 3rd trimester (Concheiro-Guisan and Concheiro, 2014). The 
main disadvantage of meconium is its collection; it may be delayed up to 5 days after birth, 
and if it passes before birth, drug testing cannot be performed. 
Due to these reasons, umbilical cord has been suggested as an alternative specimen 
to detect in utero drug exposure. Umbilical cord is abundant, its collection is non-invasive 
and easy because it is considered as waste product (Gray and Huestis, 2007; Concheiro-
Guisan and Concheiro, 2014). Although its window of detection is still not established, 
several studies showed agreement between meconium and umbilical cord results for drug 
detection, indicating a similar window of detection (Concheiro et al., 2017; Colby, 2017; 
Montgomery et al., 2006). The current data available for cannabis in umbilical cord are 
scarce (Colby, 2017; Montgomery et al., 2006; Palmer et al., 2017), and there is no 
information about the metabolite profile of THC, predominant compounds and their 





Cannabis and its metabolites have been determined in meconium (Gray, Barnes, 
and Huestis, 2010; Marchei et al., 2006; Prego-Meleiro et al., 2017; Ristimaa, Gergov, 
Pelander, Halmesmäki, and Ojanperä, 2010), but umbilical cord methods are limited  
(Chittamma, Marin, Williams, Clark, and McMillin, 2013; Montgomery et al., 2008). 
Chittamma et al.(2013) developed a method for the determination of free THCCOOH in 
umbilical cord by immunoassay ELISA and liquid chromatography – time of flight mass 
spectrometry (LC-TOF-MS). Montgomery et al. (2008) analyzed cannabinoids in 
umbilical cord by gas chromatography mass spectrometry (GC-MS), but the authors did 
not indicate which cannabinoids were investigated, and no validation data were reported.  
The aim of the present study was to develop and validate a sensitive and specific 
method for the simultaneous determination of delta-9-tetrahydrocannabinol (THC), 
cannabidiol (CBD) and five THC metabolites, 11-nor-9-caroxy-THC (THCCOOH), 11-
hydroxy-THC (THC-OH), 8-β-11-dihydroxy-THC (THC-diOH), THCCOOH-glucuronide 
and THC-glucuronide, in umbilical cord by liquid chromatography tandem mass 
spectrometry (LC-MSMS). The method was applied for the analysis of authentic umbilical 
cord samples from newborns exposed to cannabis during pregnancy.  
 
Materials and Methods 
Chemicals and reagents 
THC, THC-OH, THC-COOH and CBD at 1 mg/mL, and THCCOOH-glucuronide 
and the internal standards (IStd) THC-d3, THC-OH-d3 and THCCOOH-d3 at 0.1 mg/mL in 
methanol were purchased from Cerilliant (Round Rock, TX, USA). THC-diOH and THC-





ElSohly Laboratories (Oxford, MS, USA). Solid phase extraction (SPE) mixed-mode 
cation exchange cartridges (Strata Drug X-C, 3 mL, 60 mg) were purchased from 
Phenomenex (Torrance, CA, USA). Formic acid was obtained from Pharmco-Aaper 
(Shelbyville, KY, USA). Methanol, acetonitrile, dichloromethane, and isopropanol were 
acquired from Fisher Scientific (Pittsburgh, PA, USA). Solvents for the extraction were 
high performance liquid chromatography (HPLC) grade and for the chromatographic 
instrument were liquid chromatography-mass spectrometry (LC-MS) grade. 
Umbilical cord samples 
Blank umbilical cord samples were purchased from Lee BioSolutions (Maryland 
Heights, MO, USA), and were stored at -20 °C. Umbilical cord samples from newborns 
exposed to cannabis during pregnancy (n=13) were collected at delivery in a polypropylene 
containers and stored at -20 °C until analysis. The participant mothers were pregnant 
women who delivered at the University Hospitals of Santiago de Compostela and Vigo, 
Spain, from January 2012 to December 2015. The participants were informed about the 
study both in writing and orally before the delivery, and they gave written consent. The 
subjects were not paid for their participation. The study was approved by the Ethics 
Committee of the University of Santiago de Compostela, Spain. 
Preparation of calibration and quality control samples 
A working solution at 1 g/mL containing all analytes except THC-glucuronide 
was prepared by dilution in methanol. Working solutions containing all analytes at 0.1 
g/mL and 0.01 g/mL were prepared by dilution in methanol. IStd mixture at 0.1 g/mL 





1, 2, 7, 10, 20, 50, 100 and 200 ng/g were prepared by the addition of proper volumes of 
0.01, 0.1 or 1 g/mL working solutions to 0.5 g blank umbilical cord samples. Low and 
high QC samples were prepared at 5 and 15 ng/g for THC-glucuronide, and at 15 and 150 
ng/g for other analytes.  
Sample preparation 
0.5±0.02 g umbilical cord were weighted and cut in small pieces. Three mL of 
methanol were added, and the samples were homogenized for 5 min using a tissue 
homogenizer (OMNI International, GA, USA) at speed 5.5. After centrifugation at 4,960 
rcf at 4°C for 15 min, the supernatants were transferred to new test tubes and evaporated 
at 55°C in a TurboVap LV evaporator (Biotage, Charlotte, NC, USA). The dried samples 
were reconstituted in 3 mL of a mixture of 0.1% formic acid in water and in acetonitrile 
(70:30, v/v), vortexed and centrifuged at 4,960 rcf at 4°C for 5 min. The samples were 
loaded onto Strata X-C cartridges that were conditioned with 3 mL methanol and 3 mL 
deionized water. After loading the sample, the cartridges were washed with 2 mL of 1% 
formic acid in water and 2 mL of a mixture of 1% formic acid in water and methanol (70:30, 
v/v). The cartridges were dried under vacuum for 10 min. Elution was performed by 3 mL 
of a mixture of dichloromethane and isopropanol (30:70, v/v), and the eluates were 
evaporated at 45°C in a TurboVap LV evaporator. The dried samples were reconstituted 
with 200 L of a mixture of 0.1% formic acid in water and in acetonitrile (70:30, v/v), 






Ultra-high-performance liquid chromatography-tandem mass spectrometry 
(UHPLC-MSMS) instrument LCMS-8030 from Shimadzu (Columbia, MD, USA) was 
employed. The Nexera UHPLC system consisted of a binary LC-30AD pump, online 
degassing unit DGU-20A and cooled autosampler SIL-30AC. The triple quadrupole mass 
spectrometer with Dual Ionization Source (DUIS) was operated in the positive ionization 
mode with the following parameters: spray voltage, 4.5 kV; corona pin voltage, 4.5 kV; 
desolvation line temperature 250°C; heat block temperature 400°C; nebulizing gas flow 
rate 2 L/min and drying gas flow rate 15 L/min. Precursor to product ion transition 
optimizations were performed by injection of individual analytes at 0.01 g/mL in 
methanol without column. Each compound was monitored by 2 transitions in MRM, 
multiple reaction monitoring mode (Table 1). Chromatographic separation was conducted 
on a Kinetex F5 column, 100 × 2.1 mm, 1.7 m (Phenomenex, Torrance, CA, USA) at 
40°C. 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) were 
employed as mobile phases at a flow rate of 0.5 mL/min with the following gradient: initial 
composition of 30% B increased to 78.5% over 8.5 min, then increased to 98% over 0.2 
min, held for 3 min, and then returned to initial composition over 0.2 min and held for 2.1 











Table 1. Multiple reaction monitoring (MRM) transitions, collision energies, retention 
time (RT) and internal standard (IStd) for the cannabinoids included in the method. The 
quantifier transition is underlined. 





THC-diOH 347 > 311.2 




THC-diOH-d6 353.1 > 317.4 






521.1 > 345.1 







524.1 > 348.2 






491.4 > 315.1 





THC-OH 331.4 > 201.2 




THC-OH-d3 334.1 > 196.1 




THCCOOH 345 > 299.2 




THCCOOH-d3 348.1 > 330. 




CBD 315.4 > 192.9 




THC 315.1 > 193.1 




THC-d3 318.1 > 195.9 






The Scientific Working Group for Forensic Toxicology (SWGTOX, 2013) 
guidelines were employed for method validation. The following parameters were 
evaluated: linearity, limit of detection (LOD), limit of quantification (LOQ), carryover, 
imprecision, accuracy, matrix effect, extraction efficiency, process efficiency, 





Calibration model was evaluated with five different blank umbilical cord samples 
on five different days using five calibrator levels different from zero. Acceptable linearity 
was accomplished if the coefficient of determination (r2) was ≥ 0.95 and the residuals were 
< 20%. Limit of detection (LOD) and quantification (LOQ) were determined by fortifying 
five different sources at decreasing concentrations of compounds. Acceptance criteria for 
LOD involved signal-to noise > 3, retention time within ± 0.2 min from calibrators, and 
correct ion ratio qualifier to quantifier transition (within 20% average ion ratio of 
calibrators). LOQ met LOD criteria and had to quantify with acceptable imprecision (%CV 
< 20) and accuracy (80-120% of target concentration). Carryover was evaluated by 
injecting an extracted blank sample fortified with only IStd after an extracted sample 
fortified at the upper limit of quantification, 20 ng/g for THC-glucuronide and 200 ng/g for 
other analytes. 
Imprecision and accuracy were evaluated at low and high QC concentrations, 5 
ng/g and 15 ng/g for THC-glucuronide, and 15 ng/g and 150 ng/g for others, in triplicate 
on five different days (n=15) using umbilical cord from 5 different sources. Acceptable 
imprecision was achieved if the coefficient of variation (%CV) was less than 20%. Intra-
assay imprecision was determined by the worst imprecision from the 5 different sources 
on 5 different days, and inter-assay imprecision considering all the replicates (n=15). 
Accuracy was represented as the percentage of the target concentration and was required 
to be within 80-120%.  
For matrix effect, extraction efficiency and process efficiency evaluation, three sets 
of samples were prepared at low and high QC: blank samples fortified with analytes and 





evaluated by the comparison of the average peak area of samples fortified after extraction 
and neat solutions, (MeanAreaAfter/MeanAreaNeat - 1) x 100. Process efficiency was 
calculated by comparing the average peak area of samples fortified before extraction and 
neat solutions, (MeanAreaBefore/MeanAreaNeat) x 100. Extraction efficiency was 
calculated by the comparison of average peak areas in blank specimen fortified with 
analytes and IStd before and after extraction, (MeanAreaBefore/MeanAreaAfter) x 100.   
Endogenous interferences were analyzed in five different blank umbilical cord 
specimens fortified with only IStd. Exogenous interferences were evaluated injecting neat 
solutions at 200 ng/g of the following compounds: opiates (morphine, codeine, 6-
monoacetylmorphine), amphetamines (amphetamine, methamphetamine, MDA, MDMA, 
MDEA), cocaine (benzoylecgonine, cocaine), methadone and benzodiazepines 
(alprazolam, clonazepam, flunitrazepam, diazepam). Autosampler stability was evaluated 
by injecting low and high QC concentrations stored at 10°C for 24 h in autosampler.  
Results 
Method validation 
The calibration model was linear, with 1/x2 weighting, non-forced through zero. 
The linearity range was from 1 to 20 ng/g for THC-glucuronide, 1-200 ng/g for 
THCCOOH-glucuronide, 7-200 ng/g for THCCOOH, CBD and THC, and 10-200 ng/g for 
THC-diOH and THC-OH. The coefficients of determination (r2) of the calibration curves 
were ≥ 0.97 for all analytes, and residuals were less than 20%. The limits of detection and 
quantification ranged from 1 to 10 ng/g. Table 2 shows the results for the linearity 
parameters, linear range, and LOD and LOQ for each compound. Figure 1 shows a blank 





Table 2. Linearity parameters and limit of detection and quantification (LOD/LOQ) for 












THC-diOH 10 10-200 0.1018±0.080 0.55±0.05 0.975±0.009 
THCCOOH-
glucuronide 
1 1-200 0.1376±0.111 4.61±1.37 0.986±0.006 
THC-
glucuronide 
1 1-20 -0.1075±0.079 5.64±1.62 0.983±0.014 
THC-OH 10 10-200 -0.0237±0.110 0.35±0.08 0.979±0.003 
THCCOOH 7 7-200 0.0002±0.021 0.33±0.07 0.976±0.009 
CBD 7 7-200 0.2192±0.195 0.85±0.21 0.978±0.013 
THC 7 7-200 0.0593±0.108 0.82±0.07 0.979±0.007 
  
Imprecision and accuracy for each analyte were measured at low and high QC 
concentrations. Total imprecision ranged from 4.1 to 15.1%, intra-assay imprecision from 
7.3 to 23.4%, and accuracy ranged from 87.5 to 111.4% (Table 3).  
 
Figure1. MRM chromatograms of the quantifier (black line) and qualifier (pink line) 





for THCCOOH-glucuronide and THC-glucuronide, 7 ng/g for THCCOOH, THC and 
CBD, and 10 ng/g for THC-OH and THC-diOH.  
 
Table 3. Imprecision and accuracy in umbilical cord at low and high QC (low QC at 5 ng/g 
and high QC at 15 ng/g for THC-glucuronide, and low QC at 15 ng/g and high QC at 150 
ng/g for the other compounds). 
 
Extraction and process efficiency ranged from 25 to 45.6%, and 11.6 to 42.2%, 
respectively. Matrix effect was from -54.8 to -5.8%, with its coefficient of variation (CV) 
being ≤ 20% for all analytes, except for THC-glucuronide low QC (35.5%) and 




Analyte Intra-day Imprecision 
(CV, %, n=15) 
Inter-day Imprecision 
(CV, %,  n=15) 
Total Accuracy 
(%,  n=15) 
Low QC High QC Low QC High QC Low QC High QC 
THC-diOH 11.1 7.3 9.3 4.1 107.4 111.4 
THCCOOH-
glucuronide 
10.0 11.4 10.3 11.2 104.0 106.7 
THC-glucuronide 10.5 16.2 9.5 12.4 103.1 104.5 
THC-OH 11.8 7.8 12.8 15.1 100.4 97.6 
THCCOOH 13.4 8.0 11.1 12.6 103.9 105.2 
CBD 17.2 17.6 14.5 14.3 87.5 97.4 





Table 4. Matrix effect, extraction efficiency, and process efficiency in umbilical cord at 
low and high QC (low QC at 5 ng/g and high QC at 15 ng/g for THC-glucuronide, and low 
QC at 15 ng/g and high QC at 150 ng/g for other compounds). 
Analyte Matrix Effect  
(CV, %, n=6)  
Extraction Efficiency 
(%, n=3) 
Process Efficiency  
(%, n=3) 







































44.4 45.6 25.9 22.0 
 
No carryover was observed in a blank sample fortified with only IStd when it was 
injected after a sample fortified with the highest calibrator, 20 ng/g for THC-glucuronide 
and 200 ng/g for the other analytes. No quantifiable peaks were detected from five different 
blank umbilical cords at the retention time of each analyte. In addition, there was no 
exogenous interference from opiates (morphine, codeine, 6-monoacetylmorphine), 





(benzoylecgonine, cocaine), methadone and benzodiazepines (alprazolam, clonazepam, 
flunitrazepam, diazepam). Autosampler stability was evaluated by reinjecting three low 
and high QCs stored at 10°C for 24 h in autosampler. No loss of any analyte was observed. 
Authentic samples 
The present method was applied to thirteen authentic umbilical cord samples from 
cannabis-exposed newborns (sample ID 1-13), which meconium tested positive for THC 
and/or its metabolites, THC-OH, THC-diOH, THCCOOH, THC-glucuronide and/or 
THCCOOH-glucuronide, and for CBD. Meconium samples were analyzed by a previously 
published method (Prego-Meleiro et al., 2017).  
Six mothers denied cannabis use during pregnancy (sample ID 1, 4, 5, 8, 10 and 
12), four admitted sporadic use (sample ID 3, 6, 9 and 11) and 3 daily use (sample ID 2, 7 
and 13). Umbilical cord authentic samples were analyzed in 3 different batches. Each batch 
included a negative control (blank umbilical cord fortified with the IStd mixture only), 
calibrators, and low and high QCs.  
Twelve samples out of thirteen tested positive for cannabis in the umbilical cord. 
The analysis of these authentic samples showed a good agreement between umbilical cord 
and meconium (92.3% match). The predominant analytes in meconium samples were 
THCCOOH (n=12, 3.9 – 117.8 ng/g) and THC-diOH (n =11, 5.4 – 887.4 ng/g). Four 
samples tested positive for THCCOOH-glucuronide (19.4 – 190.2 ng/g), three samples for 
THC (3 – 15.6 ng/g) and two for THC-OH (3.7 – 164.2 ng/g). Nine samples were positive 
for CBD (9.8 – 335.3 ng/g). In the case of umbilical cord, THCCOOH-glucuronide was 
the only metabolite detected in the twelve samples at concentrations below 20 ng/g (1.6 -






Table 5. Authentic matched meconium and umbilical cord samples from thirteen newborns 

















1 3.9 21.4 0 0 3.7 0 0 
2 15.8 90 0 0 0 0 12.3 
3 14.6 85 0 0 0 9.5 1.6 
4 48.4 887.4 0 0 164.2 0 6.8 
5 9.3 18.1 19.4 0 0 18.5 16.3 
6 23.4 0 0 0 0 31.4 2.2 
7 45 53.2 190.2 5.6 0 112.1 19.1 
8 19.7 30.8 0 0 0 56.5 4.3 
9 117.8 5.4 0 15.6 0 335.3 3.6 
10 6.2 88.2 0 3 0 30.8 3.2 
11 44.4 0 67.4 0 0 74.6 14.6 
12 8.4 47.6 111.8 0 0 19.7 5.1 









Figure 2. MRM chromatograms of the quantifier (black line) and qualifier (pink line) 
transitions in an authentic umbilical cord sample (sample ID 8) positive for THCCOOH-




Although the number of pregnant women using cannabis is increasing, there are 
no accurate studies about the negative effects in fetal cannabis exposure. For the 
observation in utero drug exposure, self-report and the analysis of biological matrix are 
employed. The analysis of biological samples provides objective results while self-
reporting has inaccuracy issue.  
For the determination of in utero drug exposure, meconium, neonatal hair and urine 
are commonly used, and therefore, methods for detection of cannabis in these biological 
matrices have been published (Lozano et al., 2007; Gray, Barnes, and Huestis, 2010; Prego-
Meleiro et al., 2017; Elsohly and Feng, 1998; Feng, ElSohly, Salamone, and Salem,  2000). 
These specimens, however, have disadvantages as difficulty of collection and sample 





of collection and abundancy (Gray and Huestis, 2007; Concheiro-Guisan and Concheiro, 
2014).  
Despite these advantages, few methods have been published for determination of 
cannabis in umbilical cord (Chittamma et al., 2013; Montgomery et al., 2006; Montgomery 
et al., 2008). Montgomery et al (2006 and 2008) analyzed umbilical cord samples using a 
method developed for meconium analysis (Le, Reiter, Tomlinson, Jones, and Moore, 
2005). Cannabinoids in umbilical cord were screened by ELISA and confirmed by GC-
MS, but the methods were not validated for umbilical cord. Chittamma et al. (Chittamma 
et al., 2013) developed a method for detection of free THCCOOH in umbilical cord 
samples by ELISA and LC-TOF-MS, and compared these methods’ performance against 
results obtained by GC-MS, analyzed by a commercial laboratory (USDTL, Des Plaines, 
IL, USA). The ELISA and LC-TOF-MS methods required 1 g of umbilical cord, and the 
LOQ was 0.1 ng/g (ELISA) and 1 ng/g (LC-TOF-MS). Although our method’s LOQ for 
THCCOOH was higher (7 ng/g), the present method also confirms and quantifies THC, 
CBD and metabolites of THC as THC-OH, THC-diOH, THC-glucuronide, THCCOOH-
glucuronide in 0.5 g of umbilical cord, achieving LOQs ranged from 1 to 10 ng/g. During 
the validation, in addition, all parameters were within the range of the established criteria 
(Scientific Working Group for Forensic Toxicology, 2013), except matrix effect variability 
(CV) for THC-glucuronide at low QC (35.5%) and THCCOOH at high QC (24.2%). The 
use of the appropriate internal standard compensated for these effects, and they did not 
compromise other parameters such as precision, accuracy and LOD and LOQ. With regard 
to the chromatographic separation, we evaluated different reversed-phase stationary 





formic acid in water and acetonitrile. The main difference among the different columns 
was the glucuronides peak shape and resolution between CBD and THC. The best results 
were obtained with the F5 phase. 
Currently there are scarce data about the utility of umbilical cord to detect cannabis 
exposure during pregnancy (Colby, 2017; Palmer, Wood, and Krasowski, 2017; 
Chittamma et al., 2013), and there is no information about the predominant metabolites 
detected in this matrix. It is important to know this information because false negative 
results may occur from variations in the forms of THC metabolites present in a biological 
sample. Chittamma et al. (2013) reported free THCCOOH concentrations in umbilical cord 
from 0.06 to 6.09 ng/g (n=7), while we found only THCCOOH-glucuronide at 
concentrations between 1.6 and 19.1 ng/g in twelve umbilical cord samples from newborns 
exposed to cannabis during pregnancy using LC-MSMS. We did not detect free 
THCCOOH, but our LOQ was 7 ng/g, higher than the concentrations previously reported 
for this metabolite (0.06 -6.09 ng/g) (Chittamma et al., 2013). Glucuronide metabolites 
have been reported as the predominant analytes in umbilical cord for other drugs, such as 
buprenorphine (Concheiro et al., 2010) and morphine (Concheiro et al., 2017; Concheiro, 
et al., 2013). Umbilical cord has three blood vessels surrounded by Wharton’s jelly, which 
is a gelatinous substance mainly made up of mucopolysaccharides, highly polar 
compounds that attrack water (Naro, Ghezzi, Raio, Franchi, and D'Addario, 2001). This 
composition of the tissue may explain why polar metabolites such as glucuronides are 
accumulated in this matrix. In the present study, only one segment of the umbilical cord 
samples was analyzed, since homogeneous distribution of different types of analytes in this 





We analyzed thirteen umbilical cord samples from newborns, whose meconium 
tested positive for THC, its metabolites, and/or CBD, and twelve out of thirteen were 
positive in umbilical cord, showing a 92.3% agreement; however, the metabolite profile 
was different in both matrices. In umbilical cord, only THCCOOH-glucuronide was 
detected, while free THCCOOH and THC-diOH were the predominant analytes in 
meconium, as previously reported (Gray, Allan and Huestis, 2010; Feng et al., 2000; 
Elsohly et al., 1998). Montgomery et al. (2006) reported a 90.7% agreement between 
meconium and umbilical cord for cannabinoids detection by screening assay; however, no 
information about target analytes and concentrations were reported. Colby (2017) found a 
76% agreement between umbilical cord and meconium. Out of 217 paired samples, 27 
were positive in meconium and umbilical cord, 36 positive samples in meconium and 
negative in cord, 17 positive samples in cord and negative in meconium, and 137 negative 
samples in both matrices. In that study, only THCCOOH was analyzed in meconium 
(confirmation cut-off 5 ng/g in GC-MS) and in umbilical cord (screening cut-off 150 ng/g 
in ELISA). Although the authors stated that the Chittamma et al. (2013) method was 
employed for the analysis of umbilical cord samples (cut-off of 0.1 ng/g in ELISA, 1 ng/g 
in LC-TOF), a surprisingly higher THCCOOH cut-off in umbilical cord (150 ng/g) was 
reported. Palmer et al. (2017) reported non-difference between meconium and umbilical 
cord in overall detection of cannabis exposure during pregnancy. In this study, meconium 
and umbilical cord samples were not paired, and a comparison of the number of cases 
detected with these matrices was performed (7.7% in meconium, 9% in umbilical cord). 





confirmatory method, while umbilical cord samples were screened by ELISA for free 
THCCOOH (Chittamma et al., 2013) without confirmation.  
A limitation of the present study could be that only umbilical cord samples, whose 
meconium tested positive to cannabis, were analyzed. Therefore, we did not evaluate if 
umbilical cord samples could have tested positive and meconium negative. Based on the 
obtained results, this situation may be marginal, but further research should be performed. 
Another observation it is the higher concentrations observed in meconium compared to 
umbilical cord, and the different metabolite pattern in both biological samples. The 
different composition of the umbilical cord tissue and meconium, the physicochemical 
properties of the compounds, fetal metabolism, maternal dosing and timing may influence 
different accumulation in meconium and umbilical cord. The inclusion of additional 
metabolites, such as THC-OH glucuronide, which has been reported in meconium samples 
(Gray, Allan and Huestis, 2010; Feng et al., 2000; Elsohly et al., 1998), may improve the 
umbilical cord detection.  More data are necessary to confirm THCCOOH-glucuronide as 
predominant metabolite in umbilical cord, to evaluate additional THC biomarkers in this 
biological sample, and to establish its window of detection and its toxicological 
interpretation.   
Conclusion 
We developed and validated a specific and sensitive method for the determination 
of THC, its metabolites, including THC and THCCOOH glucuronides, and CBD in 
umbilical cord samples by LC-MSMS. The analysis of authentic samples showed the 
umbilical cord usefulness to detect cannabis in utero exposure, and that THCCOOH-
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